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Abstract: Introduction: Metagenomic sequencing is increasingly being used in clinical settings for difficult
to diagnose cases. The performance of viral metagenomic protocols relies to a large extent on the bioin-
formatic analysis. In this study, the European Society for Clinical Virology (ESCV) Network on NGS
(ENNGS) initiated a benchmark of metagenomic pipelines currently used in clinical virological labora-
tories. Methods: Metagenomic datasets from 13 clinical samples from patients with encephalitis or viral
respiratory infections characterized by PCR were selected. The datasets were analyzed with 13 different
pipelines currently used in virological diagnostic laboratories of participating ENNGS members. The
pipelines and classification tools were: Centrifuge, DAMIAN, DIAMOND, DNASTAR, FEVIR, Genome
Detective, Jovian, MetaMIC, MetaMix, One Codex, RIEMS, VirMet, and Taxonomer. Performance,
characteristics, clinical use, and user-friendliness of these pipelines were analyzed. Results: Overall, viral
pathogens with high loads were detected by all the evaluated metagenomic pipelines. In contrast, lower
abundance pathogens and mixed infections were only detected by 3/13 pipelines, namely DNASTAR,
FEVIR, and MetaMix. Overall sensitivity ranged from 80% (10/13) to 100% (13/13 datasets). Overall
positive predictive value ranged from 71-100%. The majority of the pipelines classified sequences based
on nucleotide similarity (8/13), only a minority used amino acid similarity, and 6 of the 13 pipelines
assembled sequences de novo. No clear differences in performance were detected that correlated with
these classification approaches. Read counts of target viruses varied between the pipelines over a range
of 2-3 log, indicating differences in limit of detection. Conclusion: A wide variety of viral metagenomic
pipelines is currently used in the participating clinical diagnostic laboratories. Detection of low abundant
viral pathogens and mixed infections remains a challenge, implicating the need for standardization and
validation of metagenomic analysis for clinical diagnostic use. Future studies should address the selective
effects due to the choice of different reference viral databases.
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A B S T R A C T   
Introduction: Metagenomic sequencing is increasingly being used in clinical settings for difficult to diagnose cases. 
The performance of viral metagenomic protocols relies to a large extent on the bioinformatic analysis. In this 
study, the European Society for Clinical Virology (ESCV) Network on NGS (ENNGS) initiated a benchmark of 
metagenomic pipelines currently used in clinical virological laboratories. 
Methods: Metagenomic datasets from 13 clinical samples from patients with encephalitis or viral respiratory 
infections characterized by PCR were selected. The datasets were analyzed with 13 different pipelines currently 
used in virological diagnostic laboratories of participating ENNGS members. The pipelines and classification 
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tools were: Centrifuge, DAMIAN, DIAMOND, DNASTAR, FEVIR, Genome Detective, Jovian, MetaMIC, metaMix, 
One Codex, RIEMS, VirMet, and Taxonomer. Performance, characteristics, clinical use, and user-friendliness of 
these pipelines were analyzed. 
Results: Overall, viral pathogens with high loads were detected by all the evaluated metagenomic pipelines. In 
contrast, lower abundance pathogens and mixed infections were only detected by 3/13 pipelines, namely 
DNASTAR, FEVIR, and metaMix. Overall sensitivity ranged from 80% (10/13) to 100% (13/13 datasets). Overall 
positive predictive value ranged from 71-100%. The majority of the pipelines classified sequences based on 
nucleotide similarity (8/13), only a minority used amino acid similarity, and 6 of the 13 pipelines assembled 
sequences de novo. No clear differences in performance were detected that correlated with these classification 
approaches. Read counts of target viruses varied between the pipelines over a range of 2-3 log, indicating dif-
ferences in limit of detection. 
Conclusion: A wide variety of viral metagenomic pipelines is currently used in the participating clinical diagnostic 
laboratories. Detection of low abundant viral pathogens and mixed infections remains a challenge, implicating 
the need for standardization and validation of metagenomic analysis for clinical diagnostic use. Future studies 
should address the selective effects due to the choice of different reference viral databases.   
1. Introduction 
Viral metagenomic next-generation sequencing (mNGS) is increas-
ingly being used in virology laboratories for the diagnosis of patients 
with suspected but unexplained infectious diseases. The current main 
clinical application of viral metagenomics is for diagnosing encephalitis 
of unknown cause [1,2], but metagenomic sequencing is considered 
useful in a growing number of other clinical syndromes [3–6]. Although 
many wet-lab challenges need to be faced as well [14], the performance 
of metagenomic methods is largely dependent on accurate bioinformatic 
analysis, and both classification algorithms and databases are crucial 
factors determining the overall performance of the pipelines [7,55]. A 
wide range of metagenomic pipelines and taxonomic classifiers have 
been developed, commonly for the purpose of biodiversity studies 
analyzing the composition of the microbiome in different cohorts. In 
contrast, when applying metagenomics to patient diagnostics, potential 
false-negative and false-positive bioinformatic classification results can 
have significant consequences for patient care. Most reports on bio-
informatic tools for metagenomic analysis for virus diagnostics typically 
describe algorithms and validations of single in-house developed pipe-
lines developed by the authors themselves [8–12]. Most reports on 
bioinformatic tools for metagenomic analysis for virus diagnostics 
typically describe algorithms and validations of single in-house devel-
oped pipelines developed by the authors themselves [13], and recently a 
metagenomic benchmarking trial among Swiss virology laboratories has 
been conducted [7]. Recently, ESCV Network on NGS (ENNGS) recom-
mendations for the introduction of next-generation sequencing in clin-
ical virology, part II: bioinformatic analysis and reporting were 
published [55], aiming to address the challenges involved. While a 
professional External Quality Assessment (EQA) program is currently in 
preparation by Quality Control for Molecular Diagnostics (QCMD), the 
ENNGS [14,55] conducted the presented benchmark of bioinformatic 
pipelines of the participating diagnostic laboratories using viral meta-
genomic datasets derived from clinical samples, in order to assist labo-




To exclude differences in wet-lab procedures, the same raw, un-
trimmed metagenomic datasets were provided, so that the participants 
had standardized datasets for bioinformatic analysis. 
In total, 13 clinical metagenomic datasets from samples well- 
characterized by RT-PCR [15–18] were selected from patients with en-
cephalitis or respiratory complaints, including: cerebrospinal fluid (CSF, 
n = 4), brain biopsies (n = 3), nasopharyngeal swabs (n = 3), nasal 
washings (n = 1), bronchoalveolar lavage (n = 1), and a plasma sample 
(n = 1). RT-PCR panel results and Cq-values are included in the result 
section. The pathogens in the 13 datasets are depicted in Table 2. 
For samples processed at the Great Ormond Street Hospital, London 
(GOSH), mRNA from the three brain biopsy samples was sequenced on 
an Illumina NextSeq500 instrument using an 81 bp paired-run after li-
brary preparation using Illumina’s TruSeq Stranded mRNA LT sample 
preparation kit (p/n RS-122-2101) according to the manufacturer’s in-
structions [19]. The other samples were spiked with Equine Arteritis 
Virus (EAV) and Phocid Herpes Virus (PhHV) internal controls preced-
ing total nucleic acid extraction using the MagNAPure 96 DNA and Viral 
NA Small Volume Kit (Roche Diagnostics, Almere, the Netherlands) and 
sequenced on Illumina NextSeq500 (respiratory samples) or Nova-
Seq6000 (CSF samples, plasma) instruments using 150 bp paired-end 
runs after library preparation using New England BioLabs’ NEBNext 
Ultra Directional RNA Library preparation kit for Illumina with in-house 
adaptations in order to enable simultaneous detection of both DNA and 
RNA viruses, at the Leiden University Medical Center (LUMC) [4,20]. 
Three of the CSF samples were sequenced after enrichment using cap-
ture probes targeting vertebrate viruses [21]. Human reads from the 
output FASTQ files were removed after mapping them to human refer-
ence genome GRCh38 [22] with Bowtie2 version 2.3.4 [23] before the 
datasets were uploaded to various data sharing platforms (see below). 
2.2. Data sharing 
The FASTQ datasets were and remain publicly available for user- 
friendly downloading at https://veb.lumc.nl/CliniMG (hosted by the 
dept. MM, LUMC, Leiden), and part of the datasets were additionally 
accessible via a COMPARE Data Hub at http://www.ebi.ac.uk/ena/path 
ogens (hosted by the European Bioinformatics Institute, EMBL-EBI) 
[24]. 
2.3. Bioinformatic pipelines 
The datasets were analysed in a blinded fashion by the participants, 
with the (viral) metagenomic pipelines and classification tools (Fig. 1 
and Table 1) used at their diagnostic laboratories: Centrifuge [25], 
DAMIAN [26,27], DIAMOND [28], DNASTAR [29], FEVIR [30], 
Genome Detective [31], Jovian [32], MetaMIC [33], metaMix [34,35], 
One Codex [36], RIEMS [37,38], Taxonomer [39], and VirMet [40]. 
DAMIAN was run by two participants in combination with a different 
database (pipeline A and B), and one participant run both Centrifuge and 
GenomeDetective. Details of the algorithms are described in Table 1. 
2.4. Performance characteristics 
Both qualitative and quantitative performance of the pipelines were 
analysed with real-time PCR results as gold standard. The following 
parameters available for all pipelines were considered: pathogen 
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detection, taxonomic classification level and target read count. Addi-
tionally, horizontal genome coverage (if available), computational time, 
user-friendliness and output formats were considered. Since EAV and 
PhHV were added as internal controls and not reported by the partici-
pants (due to default reporting criteria, or absence in the database)they 
were not included in the comparative analysis. 
3. Results 
3.1. Metagenomic pipeline characteristics 
In total 13 different metagenomic pipelines and classification tools 
were in use in the 13 participating diagnostic laboratories. Clinical use, 
classification and output characteristics of the pipelines and tools uti-
lized are shown in Fig. 1 and Table 1. The majority of the pipelines were 
developed or adapted at a local site, while four pipelines were 
commercially available and web-based: DNASTAR (Madison, WI, USA), 
Genome Detective (Emweb bv, Herent, Belgium), One Codex (San 
Francisco, USA), and Taxonomer (Utah, USA). DAMIAN and Centrifuge 
are publicly available as an open source software. Both classification 
tools and reference databases differed among participants (and were 
fixed for end-users of the commercially available pipelines); (adapted 
versions of) NCBI’s nucleotide and RefSeq databases were most 
commonly used to generate reference databases. Six of the 13 pipelines 
assembled sequence reads de novo, whereas the others classified unas-
sembled reads. The majority of the pipelines classified reads based on 
nucleotide similarity (8/13), and a minority used amino acid similarity 
(2/13), or a combination of both (3/13 pipelines). Parameters used by 
the participants for defining a positive result were the number of virus 
reads, horizontal genome coverage (some of the participants), and a cut- 
off based on posterior-probability scores of the species presence (meta-
Mix) and ROC-curves. Output formats varied, the majority had a user- 
friendly output format: excel, PDF or interactive webpage. Examples 
of these user-friendly output formats are shown in Supplementary 
Figure S1. 
3.2. Detection of PCR targeted viral pathogens; sensitivity 
The qualitative and quantitative results of the pipeline bench-
marking for viruses detected by RT-PCR are shown in Table 2 and Fig. 2. 
Overall, higher abundance viral pathogens (Cq-value < 28) were 
detected by all metagenomic pipelines evaluated. In contrast, viral 
pathogens with RT-PCR Cq-value of 28 and higher including mixed virus 
infections were only detected by 3/13 pipelines, namely DNASTAR, 
FEVIR, and metaMix. Although participants analysed the same FASTQ 
files, read counts of the target viruses varied from one to several orders 
of magnitude across pipelines. Also, read counts (all datasets combined) 
achieved by participants did not correlate well with the viral load as 
measured by RT-PCR (R = -0.07, P-value 0.5), however it must be noted 
that wet lab procedures varied per set of samples, including protocols 
with and without viral enrichment, which had potential impact on the 
viral read counts and thus on correlation with Cq-values. Overall 
sensitivity of the pipelines at sample level was 77% (10/13) - 100% (13/ 
13 samples, mixed infections counted as one) (Table 2 and Supple-
mentary Table 2). At viral mNGS hit level, overall sensitivity was 80% 
(12/15) - 100% (15/15 viral hits) (Supplementary Table 4). One of the 
participants reported normalized reads including the genome length, 
using the following formula: RPKM = (number of reads mapped to virus 
genome Y * 106) / (total number of reads * length of genome in kp). This 
formula was also used to normalize the reads of all study pipelines 
shown in Fig. 2. 
Fig. 1. Workflow of bioinformatic analysis of (viral) metagenomics data with the pipelines and classification tools used by participants in the current study.  
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Table 2 
Qualitative and quantitative results: raw sequence read count categories of the PCR positive viruses reported by the metagenomic pipelines using datasets from 13 
clinical samples, per classification tool (complete pipeline details can be found in Table 1). CSF; cerebrospinal fluid, NP; nasopharyngeal, BAL; bronchoalveolar lavage, 
and in legend: ND; not detected.  
Fig. 2. Sequence read counts (Y) versus RT-PCR Cq values (X) of the PCR positive viruses using datasets from 13 clinical samples, per classification tool with read 
counts reported by the participants (complete pipeline details can be found in table 1). Each vertical series of dots represents one clinical sample. The different wet 
lab methods used are marked (^ mRNA sequencing, $ RNA/DNA sequencing, and #: a captured approach using probes targeting vertebrate viruses). RPKM; reads per 
kilobase of genome per million mapped reads. 
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3.3. Taxonomic level of classification 
The taxonomic levels of classification and typing of pathogenic vi-
ruses by the metagenomic pipelines with the settings used and reported 
by the participants are shown in Fig. 3 and Supplementary Table 3. The 
classification level is dependent on the database used, algorithm settings 
(classification of reads to the lowest common ancestor, LCA, in case of 
multiple hits), and the participant’s default reporting levels based on 
either in-house validation data or clinical relevancy. Species level clas-
sification was the most common level reported. Serotype and strain level 
were identified by tools that were combined with NCBI’s nt database 
without the LCA setting. DAMIAN was the only tool to report classifi-
cation at the isolate level. 
For the Adenovirus sample (#13), virus types reported were not 
consistent between different pipelines: human Adenovirus type 31 
(DIAMOND, Jovian, DNASTAR, VirMet), type 12 (DAMIAN), type 31 or 
61 (metaMIC), indicating that type classification was not always correct. 
Type 12 and 31 are both from subgroup A Adenoviruses, whereas type 
61 is a type 31 recombinant virus. 
Fig. 3. (Taxonomic) level of classification and typing of the pathogenic viruses identified using the combination of tools and databases, as reported by participating 
diagnostic laboratories. Depicted are the number of target viruses per classification level.RefSeq; NCBI’s RefSeq data base (or an adapted version), NT; NCBI’s 
nucleotide database (or an adapted version); LCA; lowest common ancestor. *Taxonomic assignment method described in [25,26] 
Fig. 4. Sensitivity and positive predictive value based on the hits reported by the participants, for the different pipelines/classification tools.  
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3.4. Additional virus hits and positive predictive value 
Additional viruses, either not tested for by RT-PCR or RT-PCR 
negative were reported by 11 out of 13 pipelines, and in one or more 
samples (Supplementary Table 4). The following additional viruses 
were reported by multiple pipelines and absent in the negative run 
control (dataset not available for the participants): human retrovirus 
RD114 (2-2102 reads, up to 28% genome coverage), feline leukemia 
virus (2-1406 reads), torque-teno virus (TTV) (18-66 reads, up to 7% 
genome coverage), polyomaviruses (5-41 reads, up to 37% genome 
coverage), Bovine viral diarrhea virus (BVDV) (6-220 reads, likely FBS 
contaminants), human metapneumovirus (HMPV) (15-21 reads, 9% 
genome coverage), human rhinovirus (HRV) (2-4 reads, up to 5% 
genome coverage), human parainfluenzavirus-4 (PIV-4) (2-6 reads) and 
Dengue virus (18-370 reads). RT-PCR data were available for some of 
the additional viruses detected (Supplementary Table 4). When 
considering viral mNGS hits with negative RT-PCR results: CoV-NL63 (1 
read), PIV-4 (2-6 reads), HRV-C (2-4 reads), CoV-OC43 (5 reads), INF-B 
(2 reads), the positive predictive value ranged from 71-100% (Fig. 4). It 
must be noted that for these mNGS hits, no distinction could be made 
between assignments of sequences genuinely present e.g. by index 
hopping (which was suspected given the low number of reads), false 
negative by PCR due to primers/probes mismatches, and false positive 
assignments. When considering the mNGS findings without available 
RT-PCR results, retrovirus RD114, leukemia viruses, TTV, and poly-
omaviruses sequences may actually be present given their association 
with the host (integrated or commensal). 
3.5. Reporting criteria 
Reporting criteria used by the participants are shown in Table 1: a 
threshold for number of reads, for genome coverage (number of nucle-
otides and proportion of the genome, or a certain number of genome 
regions covered), based on reference or in-house validation studies. A 
BLAST analysis of matching sequences was commonly used by the study 
participants to exclude false positive (or to confirm true positive) hits. 
Some participants indicated that for clinical samples outside of the 
current benchmark, they required a confirmatory PCR before reporting 
while others indicated that this was not needed based on experiences 
from their validation studies. 
4. Discussion 
This study aimed to benchmark the combination of bioinformatic 
tools and databases currently in use in diagnostic virology laboratories 
from the ESCV ENNGS network. The data presented here support bio-
informatic selection and optimization of software for the implementa-
tion of viral metagenomic sequencing for pathogen detection in clinical 
samples. To our knowledge, this is the first large-scale international 
benchmarking study using datasets from clinical samples and pipelines 
currently applied in a large series of clinical diagnostic laboratories. 
The study showed that the pipelines of all the participating labora-
tories succeeded in detecting viral pathogens with relative high viral 
loads (Cq-values <28), whereas lower abundant pathogens and mixed 
infections were only detected by some of the pipelines, namely DNAS-
TAR, FEVIR, and metaMix. These results are in line with other reports 
[7]. With regard to mixed infections, the less abundant viruses were 
generally missed, possibly due to the low number of reads, or reporting 
considerations. For the missed CoV-HKU1 virus, potential primer 
cross-reactivity with CoV-NL63 viruses was excluded by in silico anal-
ysis. The databases used in the pipelines were mostly custom-made, 
based on either NCBI’s RefSeq [41] or nt database [42]. All of the par-
ticipants used different classification tools, though no selection of lab-
oratories using different tools was made in advance. Given the inclusion 
of different types of pipelines including commercially available ones 
with fixed databases, it was not feasible to compare the different tools 
with one standardized database at the local sites. Two of the three 
pipelines that reached 100% sensitivity included NCBI’s nt database but 
this was also seen using a pipeline with NCBI’s RefSeq database. Pipe-
lines with NCBI’s nt database scored both low and maximum precision. 
The design did allow for comparison of the complete pipeline in use for 
clinical diagnostics, from QC to reporting algorithms including posterior 
probability scores. No clear differences were observed in terms of per-
formance based on nucleotide-based classification versus amino 
acid-based classification and de novo assembly-based algorithms versus 
read based classification: whereas amino-acid based classification may 
be more sensitive for detecting variants, two of the three pipelines with 
100% sensitivity used nucleotide-based classification (DNASTAR, 
FEVIR). High precision was reached by pipelines that used de novo as-
sembly but this was not essential: 3/8 pipelines with 100% precision did 
not use de novo assembly (Centrifuge, Taxonomer, One Codex). 
Reported read counts and genome coverage varied between pipelines 
up to several orders of magnitude (for read counts), explaining in part 
the differences observed in limits of detection for samples with very low 
viral load. Possibly, differences in reporting of unique versus non- 
uniquely mapped sequence reads may be related to this difference. 
Sensitivity and positive predictive value were measured, conveniently 
avoiding the proportion of true negative findings given the immense but 
unknown number of negative mNGS hits without RT-PCR data needed 
for specificity calculations. This aspect remains a limitation intrinsically 
linked to mNGS validations with clinical datasets. Datasets from nega-
tive matrix samples would have been of use for specificity calculations. 
Positive predictive value calculations were hampered by the intrinsic 
inability to distinguish between sequences actually present in the 
dataset that might be undetected by RT-PCR because of, for instance, 
primer mismatches, index hopping or contaminant sequences intro-
duced during library preparation. This may partially be overcome by 
defining mNGS consensus results as alternative golden standard, how-
ever in diagnostic settings e.g. index hopping reads should not be labeled 
positive despite being actually present in the dataset. A study design 
using synthetic data for example spiked into real-data mimicking real- 
life situations would enable accurate estimation of the specificity and 
PPV whilst taking into consideration interfering real-life factors such as 
sequences with switched indices and ‘kitome’ sequences, present in 
every single dataset. Future studies could address specificity analysis 
using artificial datasets that take into account the index hopping 
phenomenon. 
It is important to note that participants likely have optimized their 
interpretation algorithm including cut-offs for their specific workflow 
from library preparation to sequencing. A different wet lab procedure 
(sequencer with or without index hopping, preparation with or without 
probe enrichment) will require new validation and indexing of the 
determined cut-off values and probability values. Because this was a dry 
lab comparison exercise, the participants could not follow their routine 
wet lab workflow and confirmatory PCR steps, which may have affected 
the reporting of results. Therefore no conclusions can be drawn on the 
limit of detection of the full metagenomic workflows used in each spe-
cific laboratory. The two labs that distributed the datasets may have 
been advantageous with regard to the analyses since the cut-offs for 
defining a positive result likely have been adjusted to the specific wet lab 
procedure used. However, the scores from the pipelines in use in these 
labs were not higher for the specific datasets delivered, in contrast, all 
pipelines detected all samples distributed by lab A, and other partici-
pants were more successful in detection some of the most challenging 
samples distributed by lab B. 
Genome coverage and depth was not always taken into account by 
the participating laboratories, however can be an effective parameter to 
distinguish between (PCR-)contaminants, often indicated by high depth 
at a small (PCR amplicon) region of the genome, and true positives [21, 
55]. In five of participating laboratories a cut-off of one single read was 
chosen for defining a positive mNGS result. While potentially at higher 
risk of reporting false positive results, the PPV of these pipelines ranged 
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from 72 up to 100%, indicating that this cut-off was dependent on the 
overall steps of the analysis and reporting. ROC analysis was used to find 
the optimal balance between sensitivity and specificity [20]. 
Finally, our taxonomic results are in line with data available from 
other groups [43]: the pipelines performed well at species level but 
deeper level classification was subject to less reliable classification in 
some cases. 
In conclusion, a wide variety of viral metagenomic pipelines with 
overall high sensitivity are currently used in the ESCV ENNGS partici-
pating clinical diagnostic laboratories. Detection of low abundance viral 
pathogens or mixed infections remains a challenge, implicating the need 
for standardization and validation of metagenomic analysis for clinical 
diagnostic use [44]. The algorithm for defining positive results and 
rejecting false positive results is critical and should be evaluated indi-
vidually for every workflow, which includes genome extraction, library 
preparation, sequencer and bioinformatic pipeline. Identification of 
deeper taxonomic levels is challenging, dependent on the individual 
types present in the reference database, and should be validated sepa-
rately to prevent misidentification. 
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